Craig-Hallum bullish on LifeVantage, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Interest in weight loss is at an all-time high and LifeVantage’s MindBody GLP-1 System is well positioned as an alternative to powerful new weight loss drugs, says the firm. New GLP-1 drugs like Ozempic are highly effective but can lead to muscle loss and gastrointestinal discomfort. This has created a big opportunity for LifeVantage to leverage its seller network and decades of work in nutrigenomics to launch a weight management solution to naturally boost the body’s GLP-1 production, which the company launched in October, Craig-Hallum argues. With a market that is ripe for LifeVantage’s offering and substantial early success, the firm sees potential to scale to $400M of revenue and $60M of adj. EBITDA in the next three years, well ahead of current estimates.